Bio-Rad Laboratories, Inc. Class A Common Stock vs RLX Technology Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while RLX Technology Inc trades at $1.98 (market cap $2.42B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.9× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | RLX | |
|---|---|---|
Market Cap | $9.43B | $2.42B |
Sector | Health | Technology |
52-Week High | $356.25 | $2.73 |
52-Week Low | $241.71 | $1.79 |
Enterprise Value | $9.18B | $1.04B |
Dividend Yield | — | 5.05% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →